image of Onur Cil
  • Telehealth Visits
bch logo

Onur Cil, MD, PhD

Pediatric Nephrology • Nephrology
Pediatric Kidney Disease (Nephrology) Greenbrae
877-822-4453
image of Onur Cil
image of Onur Cil
bch logo

Onur Cil, MD, PhD

Pediatric Nephrology • Nephrology
Pediatric Kidney Disease (Nephrology) Greenbrae
877-822-4453
  • Telehealth Visits

On this page

About me

Dr. Onur Cil is a pediatric nephrologist who cares for children with any form of kidney disease. He has a special interest in kidney stones, nephrotic syndrome and genetic diseases of the kidney.

Cil's laboratory research focuses on discovering potential new drugs to address kidney diseases in children, with the ultimate goal of advancing them to clinical trials and establishing better and safer treatments. Some of his discoveries have been related to diseases for which there are no existing treatments.

Cil earned his medical and doctoral degrees from Hacettepe University in Turkey, where he also completed a residency in pediatrics. He then joined UCSF as a scientist and completed a fellowship in pediatric nephrology.

Cil is a member of the American Society of Nephrology, American Society of Pediatric Nephrology and American Heart Association.

Education

Fellowship

  • Pediatric Nephrology, UCSF School of Medicine -GME

Residency

  • Pediatrics, Hacettepe University Faculty of Medicine

School

  • MD, Hacettepe Universitesi

Academic Title

  • Professor-in-Residence

Care Keywords

  • Services
    • Pediatric Nephrology
    • Nephrology

Locations

    Provider Research Listing

    Browse clinical trials and publications by this provider

    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

    For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.

    The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.